Evidence map›Paper›PMID 42003773›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell-Type-Specific TGFβ Modulators.

Maarten van Dinther, Tristin Schwartze, Jiying Zhang, Kun Fan, Gerard van der Zon, Luke Power, Cynthia S Hinck, Claire Ciancia, Ananya Mukundan, Roman Gonzalez-Prieto and 4 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Maarten van DintherOncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-9451-8884
Tristin SchwartzeDepartment of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0306-3288
Jiying ZhangOncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0009-0008-6546-3686
Kun FanOncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0009-0004-1270-6913
Gerard van der ZonOncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-6195-4356
Luke PowerCentre for Parasitology, School of Infection and Immunity, University of Glasgow, Glasgow, UK.
Cynthia S HinckDepartment of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Claire CianciaCentre for Parasitology, School of Infection and Immunity, University of Glasgow, Glasgow, UK.
Ananya MukundanDepartment of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-1161-4158
Roman Gonzalez-PrietoAndalusian Center for Molecular Biology and Regenerative Medicine, Universidad de Sevilla - CSIC - Universidad Pablo de Olavide, Sevilla, Spain.ORCID https://orcid.org/0000-0001-8997-2321
Peter van VeelenCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Rick M MaizelsCentre for Parasitology, School of Infection and Immunity, University of Glasgow, Glasgow, UK.ORCID https://orcid.org/0000-0003-3216-1944
Andrew P HinckDepartment of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-3320-8054
Peter Ten DijkeOncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-7234-342X

Funding

Structure and Functionof a Parasitic TGF-beta Mimic, TGMF30AI157069 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MUKUNDAN, ANANYA · 2021 to 2022
$103k
Chinese Scholarship CouncilNIAID NIH HHS F30 AI157069NIH HHS F30AI157069NIH HHS R03AI53915Oncode Institute base fund and NWOWellcome TrustWellcome Trust 306173
6 · The paper itself

Abstract

Heligmosomoides polygyrus, a mouse parasite, modulates host immunity by secreting modular transforming growth factor-β (TGFβ) mimics (TGMs). The agonist TGM1 interacts with TGFBR1, TGFBR2, and the co-receptor CD44 through domains D1/2, D3, and D4/5, respectively. In contrast, the antagonist TGM6, which lacks D1/2, but retains TGFBR2 binding through D3, targets different cells compared to TGM1. The TGM6 co-receptor is unknown. Using X-ray crystallography and binding studies, we show that TGM6 preferentially binds mouse TGFBR2 over human TGFBR2, and that this is essential for its antagonistic function. We identified low-density lipoprotein receptor-related protein 1 (LRP1) and betaglycan (TGFBR3) as co-receptors for TGM6. LRP1 enhances TGM6 efficacy and is required for its antagonistic effect by promoting TGFBR2 lysosomal degradation, whereas betaglycan counteracts TGM6 in a TGFBR2-dependent manner. The modular organization of TGMs enabled us to design TGM1/6 chimeras or TGM-D3 fusion with an affibody that recognizes a specific cell-surface receptor, thereby altering cell-type specificity and functionality. Furthermore, we developed a TGFBR2 nanobody that, on its own, has no inhibitory effect but, when fused to a receptor antibody, antagonizes TGFβ by blocking TGFβ receptor interaction in a cell-selective manner. Thus, we designed programmable agents that modulate TGFβ signaling only in co-receptor-expressing cells.

Indexed as

Receptor, Transforming Growth Factor-beta Type IITransforming Growth Factor betaAnimalsCrystallography, X-RayHumansLow Density Lipoprotein Receptor-Related Protein-1MiceProteoglycansReceptors, Transforming Growth Factor betaSignal TransductionbetaglycanLow Density Lipoprotein Receptor-Related Protein-1ProteoglycansReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IITransforming Growth Factor betabetaglycanbispecific antibodiesheligmosomoides polygyruslipoprotein receptor‐related proteinmolecular mimicrysignal transductiontransforming growth factor‐β

Identifiers

PMID42003773
PMCPMC13335435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.